Clinical trial
A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor
NCT01652469 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2012
- Completion date
- December 31, 2015
- Enrollment
- 81 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.